What did NHS multi-cancer test find?
Large NHS trial finds multi-cancer blood test misses target
A trial of a blood test designed to screen for more than 50 cancer types among 142,000 NHS patients did not meet its primary goal.
Results presented at an oncology conference in Chicago showed the Galleri test failed to reduce diagnoses of late-stage cancer. In other words, the evidence presented did not support the test’s central promise that it would shift cancers toward earlier detection at the population level.
The broader takeaway for public health and cancer screening is that performance in real-world screening settings can diverge from expectations based on earlier studies. When a screening tool doesn’t reduce late-stage diagnoses, it raises questions about net clinical benefit—especially given the potential for false positives and follow-up procedures that can carry physical, emotional, and system-cost burdens.
What the trial adds
- Scale: 142,000 NHS participants.
- Endpoint: reduction in late-stage cancer diagnoses.
- Finding: the test did not achieve the main aim.
This matters because the screening landscape is increasingly crowded with multi-cancer detection approaches. A high-profile failure to improve late-stage outcomes can affect payer decisions, guideline discussions, and how clinicians counsel patients about the risks and benefits of screening tests.
Even without additional details in the provided set—such as subgroup performance, positive predictive value, or specifics on cancers detected—the failure to hit the primary endpoint is a clear signal that the test did not deliver the expected population-level benefit in this study.